The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia

Guillaume Olombel,Estelle Guerin,Julien Guy,Jean-Yves Perrot,Florent Dumezy,Adrienne de Labarthe,Jean-Noël Bastie,Ollivier Legrand,Emmanuel Raffoux,Adriana Plesa,Orianne Wagner-Ballon,Edouard Cornet,Véronique Salaun,Claude Preudhomme,Xavier Thomas,Cécile Pautas,Sylvain Chantepie,Pascal Turlure,Sylvie Castaigne,Hervé Dombret

Blood（2016）

引用 60|浏览77

暂无评分

摘要

To the editor:Gemtuzumab ozogamicin (GO) is an immunoconjugate, combining an anti-CD33 monoclonal antibody to calicheamicin, a highly cytotoxic antibiotic. First developed as single agent in adults with relapsed acute myeloid leukemia (AML),[1][1] it was then evaluated in combination with

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要